Australia ends the compounding of GLP-1 copies
Pharmacists in Australia may no longer mix their own versions of semaglutide or tirzepatide. Patients are pointed back to registered brands.
Who feels it
-
Pharmacies
Rethink
Compounding these medicines is no longer allowed under the exemption that covered it.
-
Sellers
Rethink
Online clinics built on compounded supply had to change model or close that line.
-
Patients
Adjust
If you used a compounded copy, you need a registered product and a new script.
-
Prescribers
Adjust
Prescriptions for compounded GLP-1s can no longer be filled; switch patients to registered brands.
-
Payers
Worth knowing
Little direct effect; public subsidy rules did not change with this step.
What happened
Australia’s medicines regulator removed the exemption that let pharmacists compound GLP-1 receptor agonists. From 1 October 2024, mixing these medicines in a pharmacy is no longer lawful.
Why the regulator acted
The regulator pointed to safety reports, uncertain ingredient sources and dosing errors with compounded products. It also noted that registered brands were back in supply.
Who it reaches
- Patients on compounded copies need a registered product instead.
- Pharmacies lose a line of work that grew quickly during the shortage.
- Online clinics that relied on compounded supply must change how they operate.
What did not change
The rule is about making copies. It does not decide which registered brand is prescribed, or how much the public scheme pays for it.
Source Therapeutic Goods Administration notice on compounded GLP-1 receptor agonists, 2024
Spotted an error? Tell us through the contact form; we follow the corrections policy.
